Why the study?
Does intravenous guanidinobenzoyl-thrombin prevent thrombosis in mechanically injured porcine carotid arteries?
Does intravenous guanidinobenzoyl-thrombin prevent thrombosis in mechanically injured porcine carotid arteries?
Endogenous protein C activation via latent thrombin effectively blocks thrombosis in deeply injured arteries in a porcine model.
No immediate clinical implications; leaves open translation of protein C activation to human arterial thrombosis prevention.
Endogenously activated protein C is evaluated for antithrombotic activity in porcine carotid arteries subjected to mechanical trauma. Protein C is activated by intravenous administration of guanidinobenzoyl-thrombin, which binds to thrombomodulin and there deacylates to yield thrombin. The bound, transiently active thrombin yields a peak of anticoagulant activity between 5 and 10 min after infusion of the latent thrombin. Inhibition of thrombin binding in vivo by co-infusing and active-site-blocked thrombin preparation elicits acute and lethal systemic thrombosis. Nearly occlusive platelet thrombosis, which occurs within 30 min of crushing 1 cm segments of carotid arteries with a standard hemostat, is blocked by endogenous protein C activation initiated 2 min before the crush injury. It is concluded that activated protein C blocks thrombosis is deeply injured musculo-elastic arteries, and that activation of latent thrombin bound to thrombomodulin in vivo is a practical means for delivery of pharmacologically effective concentrations of activated protein C.
No takes yet. Share an insight, caveat, or question.
McBane et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: